A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive cl...

Full description

Bibliographic Details
Main Authors: Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Format: Online
Language:English
Published: Springer US 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397213/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397213/

Similar Items